| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/bib/ChengHYW17 |
| P356 | DOI | 10.1093/BIB/BBW051 |
| P698 | PubMed publication ID | 27296652 |
| P50 | author | Feixiong Cheng | Q47168118 |
| P2093 | author name string | Huixiao Hong | |
| Yuquan Wei | |||
| Shengyong Yang | |||
| P2860 | cites work | Digitoxin and its analogs as novel cancer therapeutics | Q21195743 |
| The Sequence of the Human Genome | Q22065842 | ||
| An integrated encyclopedia of DNA elements in the human genome | Q22122150 | ||
| Cancer genome landscapes | Q22242276 | ||
| An open investigation of the reproducibility of cancer biology research | Q24273259 | ||
| NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling | Q24319576 | ||
| The Protein Data Bank | Q24515306 | ||
| The Reactome pathway knowledgebase | Q24567743 | ||
| Data, information, knowledge and principle: back to metabolism in KEGG | Q24568332 | ||
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| NCBI GEO: archive for functional genomics data sets--update | Q24595691 | ||
| International network of cancer genome projects | Q24611474 | ||
| Pathway Commons, a web resource for biological pathway data | Q24615770 | ||
| PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse | Q24619841 | ||
| Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer | Q24632703 | ||
| BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities | Q24675698 | ||
| Phospho.ELM: a database of experimentally verified phosphorylation sites in eukaryotic proteins | Q24801487 | ||
| Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science | Q26778374 | ||
| PREDICT: a method for inferring novel drug indications with application to personalized medicine | Q27137071 | ||
| Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation | Q27698001 | ||
| Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents | Q28087754 | ||
| WikiPathways: building research communities on biological pathways | Q28090976 | ||
| Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 | ||
| Proteogenomic characterization of human colon and rectal cancer | Q28244320 | ||
| ONCOMINE: a cancer microarray database and integrated data-mining platform | Q28255103 | ||
| Big-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals. | Q35789759 | ||
| Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation | Q35871171 | ||
| Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem | Q36097745 | ||
| Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. | Q36134167 | ||
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Q36256943 | ||
| Immunological mechanisms of the antitumor effects of supplemental oxygenation | Q36269330 | ||
| Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling | Q36406541 | ||
| ccmGDB: a database for cancer cell metabolism genes | Q36434684 | ||
| DGIdb 2.0: mining clinically relevant drug-gene interactions. | Q36434749 | ||
| Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information | Q36434850 | ||
| Mapping the effects of drugs on the immune system | Q36446799 | ||
| Psmir: a database of potential associations between small molecules and miRNAs | Q36463174 | ||
| ChemProt-2.0: visual navigation in a disease chemical biology database | Q36491224 | ||
| InnateDB: systems biology of innate immunity and beyond--recent updates and continuing curation | Q36491232 | ||
| Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach | Q36539506 | ||
| Metformin intake is associated with better survival in ovarian cancer: a case-control study | Q36557010 | ||
| Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer | Q36672248 | ||
| In silico methods for drug repurposing and pharmacology | Q36837816 | ||
| A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer | Q36903254 | ||
| The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology | Q36971433 | ||
| Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes | Q37096363 | ||
| Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium | Q37238264 | ||
| A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. | Q37395737 | ||
| Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. | Q37413146 | ||
| Computational approaches to identify functional genetic variants in cancer genomes | Q37574108 | ||
| Interaction-based discovery of functionally important genes in cancers | Q37574182 | ||
| Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases | Q37733781 | ||
| Targeting apoptosis pathways by Celecoxib in cancer | Q37846306 | ||
| A comprehensive transcriptional portrait of human cancer cell lines | Q37854720 | ||
| Understanding genomic alterations in cancer genomes using an integrative network approach | Q38069759 | ||
| Network-based drug repositioning | Q38089597 | ||
| In silico ADMET prediction: recent advances, current challenges and future trends | Q38107020 | ||
| Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development | Q38109305 | ||
| Repositioning metformin for cancer prevention and treatment | Q38114964 | ||
| Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. | Q38116255 | ||
| Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. | Q38116292 | ||
| Cancer systems biology and modeling: microscopic scale and multiscale approaches. | Q38198440 | ||
| Hot spots in protein-protein interfaces: towards drug discovery. | Q38226557 | ||
| Metformin: from mechanisms of action to therapies | Q38279824 | ||
| A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. | Q38381789 | ||
| SM2miR: a database of the experimentally validated small molecules’ effects on microRNA expression | Q38460067 | ||
| canSAR: updated cancer research and drug discovery knowledgebase | Q38488438 | ||
| Tumorigenesis: it takes a village | Q38544200 | ||
| Metformin and prostate cancer stem cells: a novel therapeutic target | Q38555403 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| Drug repurposing in oncology--patient and health systems opportunities. | Q38611707 | ||
| Clonotyping for precision oncology | Q38614405 | ||
| CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer | Q38614582 | ||
| CancerResource--updated database of cancer-relevant proteins, mutations and interacting drugs | Q38817942 | ||
| Stromal contribution to the colorectal cancer transcriptome. | Q38906913 | ||
| SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning | Q39947451 | ||
| Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit | Q41301561 | ||
| Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report | Q41491252 | ||
| PROMISCUOUS: a database for network-based drug-repositioning | Q41578922 | ||
| How good can cryo-EM become? | Q41603118 | ||
| Genome-wide analysis of noncoding regulatory mutations in cancer | Q41842692 | ||
| DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. | Q41979190 | ||
| Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease | Q41989179 | ||
| admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties | Q42673952 | ||
| GlaxoSmithKline opens the door on clinical data sharing | Q42678818 | ||
| PTMcode v2: a resource for functional associations of post-translational modifications within and between proteins | Q43214954 | ||
| Interactome3D: adding structural details to protein networks | Q44525347 | ||
| In silico drug repositioning – what we need to know | Q44525419 | ||
| Cancer modeling and network biology: accelerating toward personalized medicine | Q44772124 | ||
| Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). | Q45746424 | ||
| Personalized medicine: Time for one-person trials | Q46268988 | ||
| Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. | Q47428755 | ||
| Stromal gene expression defines poor-prognosis subtypes in colorectal cancer | Q48222476 | ||
| Adverse drug events: database construction and in silico prediction | Q51241453 | ||
| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. | Q51781980 | ||
| Cell competition is a tumour suppressor mechanism in the thymus | Q52650208 | ||
| Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types | Q54310538 | ||
| Thalidomide | Q56091164 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing | Q28275103 | ||
| Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival | Q28277824 | ||
| Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
| The BioGRID interaction database: 2013 update | Q28280503 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Discovery and saturation analysis of cancer genes across 21 tumour types | Q28305204 | ||
| How to improve R&D productivity: the pharmaceutical industry's grand challenge | Q28314992 | ||
| ChEMBL: a large-scale bioactivity database for drug discovery | Q28315179 | ||
| Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer | Q28480572 | ||
| Prediction of chemical-protein interactions network with weighted network-based inference method | Q28481329 | ||
| Prediction of drug-target interactions and drug repositioning via network-based inference | Q28483634 | ||
| Towards structural systems pharmacology to study complex diseases and personalized medicine | Q28538838 | ||
| A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types | Q28547803 | ||
| A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces | Q28550391 | ||
| The Genotype-Tissue Expression (GTEx) project | Q28657968 | ||
| Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK | Q28833740 | ||
| PubChem: a public information system for analyzing bioactivities of small molecules | Q28842768 | ||
| Human Protein Reference Database--2009 update | Q29547392 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Clonal evolution in cancer | Q29547696 | ||
| STRING v9.1: protein-protein interaction networks, with increased coverage and integration | Q29614691 | ||
| Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 | ||
| Integrative analysis of 111 reference human epigenomes | Q29615565 | ||
| COSMIC: exploring the world's knowledge of somatic mutations in human cancer | Q29615725 | ||
| STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data | Q30002336 | ||
| Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. | Q30384542 | ||
| Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease | Q30526431 | ||
| TCPA: a resource for cancer functional proteomics data | Q30666936 | ||
| Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data | Q30804500 | ||
| TCGA-assembler: open-source software for retrieving and processing TCGA data | Q30827501 | ||
| Learning from big health care data | Q30828982 | ||
| IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates | Q30990059 | ||
| Genetics: Big hopes for big data | Q31025594 | ||
| TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data | Q31034005 | ||
| Data gaps limit the translational potential of preclinical research | Q31035567 | ||
| Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines | Q33611069 | ||
| Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer | Q33667666 | ||
| Identification of small molecules enhancing autophagic function from drug network analysis | Q33712703 | ||
| LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures | Q33860855 | ||
| Pharmaco-miR: linking microRNAs and drug effects | Q33920265 | ||
| Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome | Q33923533 | ||
| Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy | Q33977022 | ||
| Discovery and preclinical validation of drug indications using compendia of public gene expression data | Q33995422 | ||
| PharmGKB: the Pharmacogenetics Knowledge Base | Q34010656 | ||
| Systematic identification of novel protein domain families associated with nuclear functions | Q34108188 | ||
| RNAi therapies: drugging the undruggable | Q34131220 | ||
| Diagnosing the decline in pharmaceutical R&D efficiency | Q34257771 | ||
| Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells | Q34282943 | ||
| Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells | Q34313686 | ||
| Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. | Q34323756 | ||
| Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking | Q34373100 | ||
| Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment | Q34385041 | ||
| mTOR-targeted therapy of cancer with rapamycin derivatives | Q34397003 | ||
| EGFR-mutated lung cancer: a paradigm of molecular oncology | Q34406334 | ||
| Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach | Q34423170 | ||
| Biological and therapeutic impact of intratumor heterogeneity in cancer evolution | Q34457994 | ||
| In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities | Q34466574 | ||
| Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans | Q34475541 | ||
| Applications of the CRISPR-Cas9 system in cancer biology | Q34479139 | ||
| Drug repositioning by structure-based virtual screening | Q34536280 | ||
| Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission | Q34611836 | ||
| An atlas of active enhancers across human cell types and tissues | Q34660689 | ||
| New uses for old drugs | Q34661227 | ||
| SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents | Q35593948 | ||
| PINA v2.0: mining interactome modules. | Q35630696 | ||
| A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy | Q35652903 | ||
| Elucidating Compound Mechanism of Action by Network Perturbation Analysis. | Q35694439 | ||
| Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses | Q35767380 | ||
| P433 | issue | 4 | |
| P921 | main subject | infrastructure | Q121359 |
| drug repositioning | Q5308921 | ||
| P304 | page(s) | 682-697 | |
| P577 | publication date | 2017-07-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Briefings in Bioinformatics | Q4967031 |
| P1476 | title | Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era | |
| P478 | volume | 18 |
| Q47343676 | Accurate prediction and elucidation of drug resistance based on the robust and reproducible chemoresponse communities |
| Q47948290 | Drug repurposing for the treatment of glioblastoma multiforme. |
| Q98626411 | Emerging strategies on in silico drug development against COVID-19: challenges and opportunities |
| Q52564950 | Gender Dimorphism Creates Divergent Cancer Susceptibilities |
| Q37701286 | IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer |
| Q91855356 | Identifying Cancer Driver lncRNAs Bridged by Functional Effectors through Integrating Multi-omics Data in Human Cancers |
| Q47168067 | In silico prediction of chemical mechanism of action via an improved network-based inference method |
| Q90482543 | Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
| Q41084007 | Precision medicine for hepatocelluar carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. |
| Q47731882 | Quantitative and Systems Pharmacology. 1. In Silico Prediction of Drug-Target Interactions of Natural Products Enables New Targeted Cancer Therapy |
| Q47397587 | Systems Bioinformatics: increasing precision of computational diagnostics and therapeutics through network-based approaches |
| Q27468694 | Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis |
| Q37708902 | Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes. |
| Q39257898 | Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer |
Search more.